CAJ | 학술논문

目的：探讨贝伐单抗联合AP方案（培美曲塞／顺铂）治疗晚期非鳞非小细胞肺癌（ NSCLC）的疗效。方法根据治疗方案将2010年1月－2011年4月江西省肿瘤医院收治的81例晚期非鳞NSCLC患者分为观察组（45例）与对照组（36例）。观察组治疗采用贝伐单抗联合AP方案，对照组治疗采用AP方案。结果①观察组化疗近期疗效显著优于对照组（P＜0．05）。②观察组与对照组中性粒细胞减少、血小板减少、呕吐、肝功能异常、肾功能异常等化疗不良反应分级相比差异无统计学意义（P＞0．05）。③观察组中位无进展生存期（mPFS）、中位总生存期（mOS）显著高于对照组（P＜0．05）。结论贝伐单抗联合AP方案治疗晚期非鳞NSCLC的近期疗效与远期疗效优于AP方案，且安全性好。
목적：탐토패벌단항연합AP방안（배미곡새／순박）치료만기비린비소세포폐암（ NSCLC）적료효。방법근거치료방안장2010년1월－2011년4월강서성종류의원수치적81례만기비린NSCLC환자분위관찰조（45례）여대조조（36례）。관찰조치료채용패벌단항연합AP방안，대조조치료채용AP방안。결과①관찰조화료근기료효현저우우대조조（P＜0．05）。②관찰조여대조조중성립세포감소、혈소판감소、구토、간공능이상、신공능이상등화료불량반응분급상비차이무통계학의의（P＞0．05）。③관찰조중위무진전생존기（mPFS）、중위총생존기（mOS）현저고우대조조（P＜0．05）。결론패벌단항연합AP방안치료만기비린NSCLC적근기료효여원기료효우우AP방안，차안전성호。
Objective To investigate the efficacy of bevacizumab and AP scheme ( pemetrexed plus cisplatin ) in the treatment of advanced non-squamous non-small cell lung cancer ( NSCLC ) .Methods 81 cases of advanced non-squamous NSCLC were divided into the observation group (45 cases) and the control group(36 cases).The observation group received bev-acizumab and AP scheme ,while the control group was given AP scheme only .Results ①The short-term efficacy of chemothera-py in the observation group was superior to control group (P<0.05).②No significant differences in the degree of neutropenia , thrombocytopenia,vomiting,hepatic dysfunction and renal dysfunction were found between the observation group and the control group(P>0.05).③The median progression-free survival time (mPFS) and median overall survival time(mOS) in the observa-tion group were significantly higher than those of the control group (P<0.05).Conclusion The short-term and long-term effi-cacy of bevacizumab and AP scheme ,which shows good safety ,are superior to AP scheme in the treatment of advanced non-squa-mous NSCLC .